Granulocyte and monocyte adsorption apheresis as an effective treatment for Reiter disease

Yoshifuku, Asuka; Oyama, Kenji; Ibusuki, Atsuko; Kawasaki, Masayuki; Sakanoue, Masanao; Matsushita, Satoru; Kawai, Kazuhiro; Kikuchi, Kôichi; Maruyama, Ikuro; Kanekura, Takuro

doi:10.1111/j.1365-2230.2011.04181.x

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mice depleted of neutrophils are completely resistant to the inflammatory effects of autoreactive immunoglobulin from K/BxN mice, a model of RA that causes rapid, joint-specific inflammatory responses [41]. In humans, the efficacy of adsorptive granulocyte and monocyte apheresis has been reported for the treatment of many inflammatory conditions, such Reiter syndrome [42], Crohn's disease [43], and ulcerative colitis [44,45]. Although crude, these methods demonstrate the positive effect that reducing neutrophil numbers can have on disease pathology.…”

Section: Discussionmentioning

confidence: 99%

A neutralizing anti–G-CSFR antibody blocks G-CSF–induced neutrophilia without inducing neutropenia in nonhuman primates

Scalzo-Inguanti

Monaghan

Edwards

et al. 2017

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Neutrophils are the most abundant WBCs and have an essential role in the clearance of pathogens. Tight regulation of neutrophil numbers and their recruitment to sites of inflammation is critical in maintaining a balanced immune response. In various inflammatory conditions, such as rheumatoid arthritis, vasculitis, cystic fibrosis, and inflammatory bowel disease, increased serum G-CSF correlates with neutrophilia and enhanced neutrophil infiltration into inflamed tissues. We describe a fully human therapeutic anti-G-CSFR antibody (CSL324) that is safe and well tolerated when administered via i.v. infusion to cynomolgus macaques. CSL324 was effective in controlling G-CSF-mediated neutrophilia when administered either before or after G-CSF. A single ascending-dose study showed CSL324 did not alter steady-state neutrophil numbers, even at doses sufficient to completely prevent G-CSF-mediated neutrophilia. Weekly infusions of CSL324 (≤10 mg/kg) for 3 wk completely neutralized G-CSF-mediated pSTAT3 phosphorylation without neutropenia. Moreover, repeat dosing up to 100 mg/kg for 12 wk did not result in neutropenia at any point, including the 12-wk follow-up after the last infusion. In addition, CSL324 had no observable effect on basic neutrophil functions, such as phagocytosis and oxidative burst. These data suggest that targeting G-CSFR may provide a safe and effective means of controlling G-CSF-mediated neutrophilia as observed in various inflammatory diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

A neutralizing anti–G-CSFR antibody blocks G-CSF–induced neutrophilia without inducing neutropenia in nonhuman primates

Scalzo-Inguanti

Monaghan

Edwards

et al. 2017

Journal of Leukocyte Biology

View full text Add to dashboard Cite

show abstract

“…It features a column containing cellulose acetate (CA) beads . Our previous clinical studies on the efficacy of GMA for treating various skin diseases and related arthropathy attributable to activated granulocytes yielded excellent results in patients with pyoderma gangrenosum (PG), pustular psoriasis (PP), psoriatic arthritis (PsA), Behçet's disease (BD), adult Still's disease, leg ulcers associated with rheumatoid arthritis, cutaneous allergic vasculitis (CAV), Reiter's disease (RD), and systemic lupus erythematosus (SLE) skin rash .…”

mentioning

confidence: 99%

Granulocyte and Monocyte Adsorption Apheresis for Refractory Skin Diseases due to Activated Neutrophils, Psoriasis, and Associated Arthropathy

et al. 2013

View full text Add to dashboard Cite

Granulocyte and monocyte adsorption apheresis (GMA), an extracorporeal apheresis instrument whose column contains cellulose acetate (CA) beads, is designed to remove activated granulocytes and monocytes. We previously demonstrated that GMA was useful for treating neutrophilic dermatoses and associated arthropathy as it adsorbs Mac-1 (CD11b/CD18)-expressing neutrophils to the CA beads by the binding of complement component (iC3b) and CD11b expressed on activated neutrophils. The objective of this study is to further assess the clinical effectiveness of GMA in the treatment of neutrophilic dermatoses and associated arthropathy. The effect of GMA for skin lesions and joint lesions was assessed in 44 and 23 patients, respectively. Mac-1 expression on peripheral neutrophils was measured by flow cytometry. Skin lesions and arthropathy improved in 39 of 44 patients (88.6%) and 22 of 23 (95.6%), respectively. Mac-1 (CD11b/CD18) expression on the peripheral neutrophils, 27.1 ± 6.66 MFI (mean fluorescence intensity) before treatment, was reduced to 17.9 ± 3.02 MFI by GMA (P < 0.05). Clinical effectiveness of GMA for the treatment of intractable neutrophilic dermatoses and associated arthropathy was further confirmed.

show abstract

“…DMARDs, such as sulfasalazine, are effective for peripheral manifestations, while most experts consider glucocorticoids use in ReA contraindicated, except for an occasional intra-articular injection (83). As ReA is attributable to activated neutrophils and it is histologically similar to pustular psoriasis in its prominent neutrophil infiltration, therapy with GMA may be useful for treating this disease, as reported by Yoshifuku et al (85). Particularly, the authors described a case of a 73-year-old man with scaly, coalescent erythematous macules with ulcers on penis and scrotum and a scaly erythematous plaque on his right hand.…”

Section: Gma In Other Skin Disordersmentioning

confidence: 97%

Use of granulocyte and monocyte adsorption apheresis in dermatology (Review)

2022

View full text Add to dashboard Cite

Adsorptive granulocyte and monocyte apheresis (GMA) is an extracorporeal treatment that selectively removes activated myeloid lineage leukocytes from peripheral blood. This technique consists of a column with cellulose acetate beads as absorptive leukocytapheresis carriers, and was initially used to treat ulcerative colitis. A literature search was conducted to extract recently published studies about the clinical efficacy of GMA in patients with different skin disorders, reporting information on demographics, clinical symptoms, treatment and clinical course. Dermatological diseases, in which GMA has been performed, include generalized pustular psoriasis, pyoderma gangrenosum, palmoplantar pustular psoriasis, Behcet's disease, Sweet's syndrome, adult-onset Still's disease, impetigo herpetiformis, reactive arthritis, acne and hidradenitis suppurativa syndrome, cutaneous allergic vasculitis and systemic lupus erythematosus. In most patients, GMA was started after the failure of conventional therapeutic options and it was helpful in the majority of cases. Based on the information summarized, GMA could be considered a valid non-pharmacological treatment option for patients with several dermatological conditions, which are difficult to treat with other pharmacological preparations.

show abstract

Granulocyte and monocyte adsorption apheresis as an effective treatment for Reiter disease

Cited by 6 publications

References 8 publications

A neutralizing anti–G-CSFR antibody blocks G-CSF–induced neutrophilia without inducing neutropenia in nonhuman primates

A neutralizing anti–G-CSFR antibody blocks G-CSF–induced neutrophilia without inducing neutropenia in nonhuman primates

Granulocyte and Monocyte Adsorption Apheresis for Refractory Skin Diseases due to Activated Neutrophils, Psoriasis, and Associated Arthropathy

Use of granulocyte and monocyte adsorption apheresis in dermatology (Review)

Contact Info

Product

Resources

About